Article

SRRM2 is a target for the immunotherapy of AML with rationally designed CAR-T cells

2023-12-06

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy that necessitates innovative treatment strategies to improve patient outcomes. The chimeric antigen receptor T cell immunotherapy (CAR-T) has emerged as a groundbreaking approach in immunotherapy; however, the lack of an optimal target antigen remains a significant impediment for CAR-T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 36dc3222-14c3-5310-952d-b082516c93f5
DOI: 10.21203/rs.3.rs-3598302/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SRRM2 is a target for the immunotherapy of AML with rationally designed CAR-T cellsDOI 10.21203/rs.3.rs-3598302/v1Read

Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate efficacy and safety in preclinical models of Multiple MyelomaSemantic proximity Read

Functional Role of Granulocytic Myeloid-Derived Suppressor Cells in CAR-T Therapy: Insights from Single- Cell RNA Sequencing in Multiple MyelomaSemantic proximity Read

Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemiaSemantic proximity Read

Non metastasis protein 2 (NME2) is a potential target for leukemia-specific immunotherapySemantic proximity Read

Characterisation and prognostic impact of ZRSR2 mutations in myeloid neoplasmsSemantic proximity Read

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advancesSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity in vivoSemantic proximity Read

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read

Single-cell immune landscape of measurable residual disease in acute myeloid leukemiaSemantic proximity Read

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read